Prevalence of gout with comorbidity aggregations in southern Taiwan

Joint Bone Spine

Volumn 82, Issue 1, 2015, Pages 45-51

  Tu, Fang Yi ^a   Lin, Gau Tyan ^b,c,d   Lee, Su Shin ^b,d   Tung, Yi Ching ^e   Tu, Hung Ping ^e   Chiang, Hung Che ^f,g  

^a Public Health Bureau   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL UNITED HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Comorbidity; Comorbidity aggregations; Gout; Prevalence

Indexed keywords

URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EVALUATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; ETHNIC GROUP; FEMALE; GOUT; HEALTH INSURANCE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ICD-9-CM; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROLITHIASIS; OBESITY; PREVALENCE; RISK FACTOR; TAIWAN; TAIWANESE; TAIWANESE ABORIGINE; URIC ACID BLOOD LEVEL; URIC ACID STONE; YOUNG ADULT;

ADULT; AGED; COMORBIDITY; GOUT; HUMANS; MALE; MIDDLE AGED; PREVALENCE; TAIWAN; YOUNG ADULT;

EID: 84922173903     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2014.07.002     Document Type: Article

References (40)

1. Richette P., Bardin T. Gout. Lancet 2010, 375:318-328.
2. Terkeltaub R.A. Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.
3. Choi H.K., Mount D.B., Reginato A.M. Pathogenesis of gout. Ann Intern Med 2005, 143:499-516.
4. Zhu Y., Pandya B.J., Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011, 63:3136-3141.
5. Roddy E., Zhang W., Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007, 3:443-449.
6. Lawrence R.C., Felson D.T., Helmick C.G., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58:26-35.
7. Adams J.U. New relief for gout. Nat Biotechnol 2009, 27:309-311.
8. Yu K.H., See L.C., Kuo C.F., et al. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res (Hoboken) 2013, 65:244-250.
9. Harris C.M., Lloyd D.C., Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol 1995, 48:1153-1158.
10. Annemans L., Spaepen E., Gaskin M., et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008, 67:960-966.
11. Kuo C.F., Grainge M.J., Mallen C., et al. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2014, doi:10.1136/annrheumdis-2013-204463.
12. Kuo C.F., Grainge M.J., See L.C., et al. Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan. Ann Rheum Dis 2013, doi:10.1136/annrheumdis-2013-204067.
13. Miao Z., Li C., Chen Y., et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 2008, 35:1859-1864.
14. Nan H., Qiao Q., Dong Y., et al. The prevalence of hyperuricemia in a population of the coastal city of Qingdao, China. J Rheumatol 2006, 33:1346-1350.
15. Klemp P., Stansfield S.A., Castle B., et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997, 56:22-26.
16. Chang S.J., Ko Y.C., Wang T.N., et al. High prevalence of gout and related risk factors in Taiwan's Aborigines. J Rheumatol 1997, 24:1364-1369.
17. Chou C.T., Lai J.S. The epidemiology of hyperuricaemia and gout in Taiwan aborigines. Br J Rheumatol 1998, 37:258-262.
18. Feig D.I., Kang D.H., Johnson R.J. Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811-1821.
19. Saag K.G., Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006, 8:S2.
20. Edwards N.L. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008, 75:S13-S16.
21. Bhole V., Choi J.W., Kim S.W., et al. Serum uric acid levels and the risk of type 2 diabetes: a prospective study. Am J Med 2010, 123:957-961.
22. Choi H.K., De Vera M.A., Krishnan E. Gout and the risk of type 2 diabetes among men with a high cardiovascular risk profile. Rheumatology (Oxford) 2008, 47:1567-1570.
23. Ko Y.C., Huang M.C., Wang T.N., et al. Prevalence and risk factors associated with dyslipidaemia in children and adolescents among ethnic groups in Taiwan. Public Health 2005, 119:489-497.
24. Choi H.K., Atkinson K., Karlson E.W., et al. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005, 165:742-748.
25. Bakris G.L., Doghramji P.P., Keenan R.T., et al. Casebook challenges: managing gout, hyperuricemia and comorbidities -- dialogue with the experts. Am J Med 2014, 127:S1.
26. Hoskison K.T., Wortmann R.L. Management of gout in older adults: barriers to optimal control. Drugs Aging 2007, 24:21-36.
27. Spiegelman D., Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005, 162:199-200.
28. Reginato A.M., Mount D.B., Yang I., et al. The genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2012, 8:610-621.
29. Tu H.P., Ko A.M., Chiang S.L., et al. Joint effects of alcohol consumption and ABCG2 Q141K on chronic tophaceous gout risk. J Rheumatol 2014, 41:749-758.
30. Cheng L.S., Chiang S.L., Tu H.P., et al. Genomewide scan for gout in Taiwanese aborigines reveals linkage to chromosome 4q25. Am J Hum Genet 2004, 75:498-503.
31. Merriman T.R., Dalbeth N. The genetic basis of hyperuricaemia and gout. Joint Bone Spine 2011, 78:35-40.
32. Ko Y.C., Wang T.N., Tsai L.Y., et al. High prevalence of hyperuricemia in adolescent Taiwan aborigines. J Rheumatol 2002, 29:837-842.
33. Becker M.A., Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am 2006, 32:275-293. [v-vi].
34. Chen J.H., Pan W.H., Hsu C.C., et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 2013, 65:133-140.
35. Riedel A.A., Nelson M., Wallace K., et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004, 10:308-314.
36. Setty A.R., Curhan G., Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007, 167:1670-1675.
37. Krishnan E., Baker J.F., Furst D.E., et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
38. Kuo C.F., See L.C., Yu K.H., et al. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology (Oxford) 2013, 52:127-134.
39. Malik A., Dinnella J.E., Kwoh C.K., et al. Poor validation of medical record ICD-9 diagnoses of gout in a veterans affairs database. J Rheumatol 2009, 36:1283-1286.
40. Kuo C.F., Yu K.H., See L.C., et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 2013, 52:111-117.